Perilli M, Segatore B, Tavio M, Setacci D, Celenza G, De Santis F, Pellegrini C, Rossolini G M, Amicosante G
Department of Sciences and Biomedical Technologies, University of L'Aquila, L'Aquila, Italy.
J Chemother. 2007 Apr;19(2):123-6. doi: 10.1179/joc.2007.19.2.123.
The present work was undertaken to study the ability of ceftazidime and ceftibuten to selectin vitro Escherichia coli HB101 harboring bla(TEM-1) beta-lactamase gene. Minimum inhibitory concentrations (MICs) of ceftazidime and ceftibuten were increased by a factor of 32, overcoming in the case of ceftazidime the breakpoint for clinical resistance. Outer membrane protein analysis and PCR for bla(TEM )alleles revealed that ceftazidime and ceftibuten select for different resistance mechanisms. Ceftazidime created mutants that encode an extended-spectrum beta-lactamase (TEM-12) and exhibit decreased expression of OmpF. Ceftibuten was unable to select for extended-spectrum beta-lactamase expressing mutants but reduced the expression of two porins, OmpC and OmpF. The stability of ceftibuten to hydrolysis and the difference in the structure of these beta-lactam antibiotics could be responsible for the selection of different mechanisms of resistance.
本研究旨在探讨头孢他啶和头孢布烯在体外筛选携带bla(TEM-1)β-内酰胺酶基因的大肠杆菌HB101的能力。头孢他啶和头孢布烯的最低抑菌浓度(MIC)增加了32倍,在头孢他啶的情况下超过了临床耐药的断点。外膜蛋白分析和bla(TEM)等位基因的PCR显示,头孢他啶和头孢布烯选择了不同的耐药机制。头孢他啶产生了编码超广谱β-内酰胺酶(TEM-12)的突变体,并表现出OmpF表达降低。头孢布烯无法筛选出表达超广谱β-内酰胺酶的突变体,但降低了两种孔蛋白OmpC和OmpF的表达。头孢布烯对水解的稳定性以及这些β-内酰胺抗生素结构的差异可能是导致选择不同耐药机制的原因。